ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 141.7 EUR | +0.05% |
|
+7.72% | +16.05% |
| 11:54am | AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal | AN |
| 09:50am | Confident start before US jobs data | AN |
| Sales 2024 * | 51.18B 47.63B 69.92B | Sales 2025 * | 54.8B 51.01B 74.88B | Capitalization | 235B 219B 322B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.52B 7.93B 11.64B | Net income 2025 * | 10.19B 9.49B 13.92B | EV / Sales 2024 * | 4.99 x |
| Net Debt 2024 * | 20.03B 18.64B 27.36B | Net Debt 2025 * | 13.54B 12.6B 18.5B | EV / Sales 2025 * | 4.54 x |
| P/E ratio 2024 * |
28
x | P/E ratio 2025 * |
23.4
x | Employees | 89,900 |
| Yield 2024 * |
2.04% | Yield 2025 * |
2.13% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | +0.05% | ||
| 1 week | +7.72% | ||
| Current month | +12.50% | ||
| 1 month | +13.63% | ||
| 3 months | +14.78% | ||
| 6 months | +19.83% | ||
| Current year | +16.05% |
1 week
132.35
143.30
1 month
122.30143.30
Current year
112.35143.30
1 year
112.35143.30
3 years
87.78143.30
5 years
64.65143.30
10 years
46.03143.30
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 141.6 | 0.00% | 13 097 |
| 24-05-02 | 141.6 | 0.00% | 32,578 |
| 24-04-30 | 141.6 | +0.21% | 14,268 |
| 24-04-29 | 141.3 | +0.71% | 22,560 |
| 24-04-26 | 140.3 | -0.60% | 28,324 |
Delayed Quote Xetra, May 03, 2024 at 06:12 am
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.9
USD
Average target price
164.5
USD
Spread / Average Target
+8.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.68% | 681B | |
| +19.40% | 556B | |
| -4.35% | 361B | |
| +17.65% | 325B | |
| +3.77% | 285B | |
| +4.48% | 199B | |
| -12.02% | 189B | |
| -3.79% | 157B | |
| -3.34% | 149B |
- Stock Market
- Equities
- AZN Stock
- ZEG Stock
